International landscape of molnupiravir patents

(For more resources, please see our page on molnupiravir.) KEI has built a dataset of patents related to molnupiravir based upon a study by Imran et al (2021), the Medicines Patent Pool (MPP) MedsPal database, and our own searches. Our… Continue Reading

Molnupiravir

Also known as EIDD-2801 or MK-4482. KEI Blogs 2021. October 22. Countries included in the Merck/molnupiravir license. 2021. October 20. International landscape of molnupiravir patents. 2021. October 4. U.S. Government’s $1.2 Billion Contract for Merck’s Investigational COVID-19 Drug Molnupiravir Redacts… Continue Reading

U.S. Government’s $1.2 Billion Contract for Merck’s Investigational COVID-19 Drug Molnupiravir Redacts IP Terms, Contains Donation Clause and Very Limited Technology Transfer License

(For more resources, please see our page on molnupiravir.) Knowledge Ecology International (KEI) has obtained a copy of the $1.2 billion contract between the U.S. government and Merck to advance purchase 1,696,629 treatment courses of molnupiravir, an investigational COVID-19 drug… Continue Reading

US government rights in patents on Molnupiravir, based upon funding of R&D at Emory University

(For more resources, please see our page on molnupiravir.) Molnupiravir, the oral pill that is showing promising results as a potential treatment for covid-19, was invented at Emory University with U.S. government funds. After more than six years of non-clinical… Continue Reading

KEI Comments on NIH Exclusive License to Ridgeback for FDA-approved Ebola Treatment

(Update: On April 30, 2021, the NIH sent a response to KEI’s comments.) On March 30, 2021, Knowledge Ecology International (KEI) filed comments regarding the National Institute of Health (NIH) National Institute of Allergy and Infectious Diseases (NIAID), “Prospective Grant… Continue Reading